Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1.1 Estimate rate of response and define acute toxicity to etanercept used in an up-front
phase II window in newly diagnosed or relapsed JMML.
1.2 Determine if response to Tumor Necrosis Factor (TNF) blockade correlates with genetic
basis of Juvenile Myelomonocytic Leukemia (JMML) [mutations in NF1, Ras, SHP2] or levels of
TNFa.
1.3 Determine if TNF blockade by etanercept results in inhibition of free levels of TNFa and
other cytokines by ELISA and bioassay and improves blood counts.
1.4 Estimate the two year event free survival and overall survival in JMML patients following
etanercept and allogeneic hematopoietic stem cell transplantation.